A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Latest Information Update: 16 Aug 2023
At a glance
- Drugs ASKG 315 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AskGene Pharma
- 09 Aug 2023 Planned initiation date changed from 9 Sep 2022 to 9 Aug 2023.
- 24 Aug 2022 New trial record